Clinical trials: Attention Deficit Hyperactivity Disorder, completed
ADHD, Attention Deficit Hyperactivity Disorder
Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD
The purpose of this study is to evaluate the safety, effectiveness, and tolerability of atomoxetine and OROS methylphenidate, taken together, in the treatment of ADHD in children and adolescents ages 6-17.
- Trial name
- NCT00585910
- Testing
- Atomoxetine and OROS Methylphenidate
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Massachusetts General Hospital
Attention Deficit Disorder With Hyperactivity
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
This study will assess the safety and tolerability of MTS while attempting to establish the appropriate starting dose for subjects previously on an existing long-acting methylphenidate product.
- Trial name
- NCT00151983
- Testing
- Methylphenidate Transdermal System
- Where
- 18 sites in United States
- Volunteers
- 175 people
- Sponsor
- Noven Therapeutics
Attention-Deficit/Hyperactivity Disorder (ADHD)
Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD
This was a randomized, double-blind, placebo-controlled, multicenter, 5-arm, parallel-group, dose-ranging study to assess the efficacy and safety of SPN-812 (Viloxazine Extended-release Capsule) in children 6-12 years of age with…
- Trial name
- NCT02633527
- Testing
- 100mg SPN-812, 200mg SPN-812, 300mg SPN-812
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit-Hyperactivity Disorder
Real World Evidence of the Efficacy and Safety of FOQUEST
This study is a four-month, phase IV, open-label study of ADHD symptomatology and functional outcomes in pediatric (6 to 17 years old) and adult (≥18 years or older) patients with ADHD treated with FOQUEST or VYVANSE.
- Trial name
- reFOQus (NCT04152629)
- Testing
- Methylphenidate Hydrochloride, Lisdexamfetamine Dimesylate
- Where
- 12 sites in Canada
- Volunteers
- 257 people
- Sponsor
- Purdue Pharma, Canada
Attention Deficit Disorder With Hyperactivity
Treatment of Severe Childhood Aggression (The TOSCA Study)
This study will determine the safety and effectiveness of two medications for treating aggression in children with attention deficit hyperactivity disorder (ADHD).
- Trial name
- NCT00796302
- Testing
- Methylphenidate HCl, Risperidone, Parent Management Training (PMT)
- Where
- 4 sites in United States
- Volunteers
- 168 people
- Sponsor
- Michael Aman
Attention Deficit Hyperactivity Disorder
Efficacy of GXR as Adjunctive Therapy With Psycho-stimulant on Executive Function in Children With ADHD
This study looks to examine whether or not INTUNIV extended release can help children aged 6-12 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD) in improving Executive Function when added to their usual care…
- Trial name
- NCT01985581
- Testing
- Guanfacine extended release, Stimulant therapy
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- JPM van Stralen Medicine Professional
Conduct Disorder, Child
Virtual Reality to Improve Social Perspective Taking
This project will examine how virtual reality treatment that provides users with the alternate perspective of a virtual interpersonal interaction impacts psychological and neurobiological markers of social perspective taking in…
- Conditions
- Conduct Disorder, Child, Adolescent, Attention Deficit and Disruptive Behavior Disorders
- Trial name
- NCT03927612
- Testing
- Virtual reality perspective taking training, Virtual reality control perspective
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Indiana University
Attention-Deficit/Hyperactivity Disorder (ADHD)
Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.
This study will evaluate the efficacy and safety of Dex-Methylphenidate Extended Release 30 mg compared to 20 mg in pediatric patients ages 6-12 with Attention-Deficit Hyperactivity Disorder (ADHD) in a 12-hour laboratory…
- Trial name
- NCT00776009
- Testing
- Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)
- Where
- 8 sites in United States
- Volunteers
- 165 people
- Sponsor
- Novartis Pharmaceuticals
ADHD, Reading/Writing Disorder
Omega-3/Omega-6 Fatty Acids for Attention-Deficit/Hyperactivity Disorder (ADHD): A Trial in Children and Adolescents
Objective: To assess whether supplementation with Omega 3/6 fatty acids (eye q®) was effective in the treatment of ADHD and its diagnostic subtypes and comorbid conditions, in children and adolescents.
- Trial name
- NCT01219309
- Testing
- Omega 3/6 fatty acids
- Volunteers
- 82 people
- Sponsor
- Göteborg University
Oppositional Defiant Disorder, Attention Deficit Hyperactivity Disorder
Randomized Controlled Trial of Comet Via the Internet or in Group Format.
The Comet-program is a Swedish parent training program developed to target externalizing behaviors in children between 3-11 years.
- Trial name
- NCT03465384
- Testing
- Comet
- Where
- 7 sites in Sweden
- Volunteers
- 161 people
- Sponsor
- Karolinska Institutet
Attention Deficit-hyperactivity Disorder
Assesment of TDApp1 an eHelath Tool to Make Therapeutic Recommendations for Patients With ADHD
This is a 3-week open label, one group study to determine the agreement between the pharmacological treatment recommended by TDApp1 and the interventions recommended by relevant clinical practice guidelines.
- Trial name
- NCT04228094
- Testing
- TDApp1: an eHealth intervention
- Where
- Spain
- Volunteers
- 33 people
- Sponsor
- Universitat de Girona
Attention Deficit Hyperactivity Disorder
The Safety and Efficacy of a Compound Natural Health Product in Children With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to investigate the use of a natural health product, as compared to placebo (an inactive substance), in managing the symptoms of ADHD.
- Trial name
- NCT01022229
- Testing
- Compound Natural Health Product
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- The Canadian College of Naturopathic Medicine
Attention Deficit Hyperactivity Disorder
Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine
The purpose of this trial is to test the value of dose increases in patients with residual ADHD symptoms after treatment with the usual target dose of atomoxetine
- Trial name
- NCT00485407
- Testing
- Atomoxetine Hydrochloride
- Where
- 2 sites in United States, Canada
- Volunteers
- 377 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
Studies of Measures of Attention
This study will compare two tests for attention deficit disorder (ADD) - the Test of Variables of Attention (TOVA) and the NIH Test of Attention - to see if they produce the same results.
- Trial name
- NCT00776737
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Institute on Deafness and Other Communication Disorders (NIDCD)
Attention Deficit Disorder With Hyperactivity
Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17
The purpose of this study is to determine the effects of SPD503 compared to placebo on tasks of sustained attention in children and adolescents aged 6-17 diagnosed with ADHD.
- Trial name
- NCT00150592
- Testing
- SPD503 (Guanfacine HCl)
- Volunteers
- 182 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder (ADHD)
Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
The study will evaluate the efficacy of LDX treatment group compared to placebo on the change from Baseline ADHD-RS-IV score at endpoint.
- Trial name
- NCT00735371
- Testing
- LDX 30 mg, LDX 50 mg, LDX 70 mg
- Where
- 45 sites in United States
- Volunteers
- 314 people
- Sponsor
- Shire
Tourette Syndrome, Tourette's Disorder
Assessment of Children With Tic Onset in the Past 6 Months
The purpose of this research is to study why most children who have tics never develop Tourette syndrome but some do. In other words, we aim to find features that may predict whose tics will go away and whose tics will continue…
- Conditions
- Tourette Syndrome, Tourette's Disorder, Chronic Motor or Vocal Tic Disorder, Transient Tic Disorder
- Trial name
- NewTics (NCT01177774)
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Washington University School of Medicine
Attention Deficit Disorder With Hyperactivity
Genetic, Brain Structure, and Environmental Effects on ADHD
Background: Attention deficit hyperactivity disorder (ADHD) is one of the most common and inheritable of all neuropsychiatric disorders. It causes problems with attention and impulse control.
- Trial name
- NCT01721720
- Where
- United States
- Volunteers
- 1,091 people, healthy volunteers welcome
- Sponsor
- National Human Genome Research Institute (NHGRI)
Attention-Deficit/Hyperactivity Disorder (ADHD)
Does Active Parent Involvement in Deliberation and Choice Improve Medication Persistence for Their Child With ADHD
The purpose of the study is to determine whether active parent involvement in deliberation and choice improves subsequent medication persistence for their child with ADHD.
- Trial name
- NCT00631280
- Testing
- Choice, Recommendation
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
ADHD
Therapeutic Effects of Pine Bark Extracts in Attention Deficit Hyperactivity Disorder
In this study, the investigators will investigate the effects of polyphenolic extract from pine bark on the inattention and hyperactivity in patients with attention deficit hyperactivity disorder (ADHD) based on antioxidative…
- Trial name
- NCT03368690
- Testing
- Oligopin®
- Where
- 2 sites in Taiwan
- Volunteers
- 32 people
- Sponsor
- Taipei Medical University